PT100975A - Compostos que tem como alvo o factor de permeabilidade vascular, constituidos por uma primeira parte de ligacao a um anticorpo especifico para vpf e por uma toxina como parte efectora - Google Patents

Compostos que tem como alvo o factor de permeabilidade vascular, constituidos por uma primeira parte de ligacao a um anticorpo especifico para vpf e por uma toxina como parte efectora

Info

Publication number
PT100975A
PT100975A PT100975A PT10097592A PT100975A PT 100975 A PT100975 A PT 100975A PT 100975 A PT100975 A PT 100975A PT 10097592 A PT10097592 A PT 10097592A PT 100975 A PT100975 A PT 100975A
Authority
PT
Portugal
Prior art keywords
vpf
toxin
constituted
factor
connection
Prior art date
Application number
PT100975A
Other languages
English (en)
Inventor
Donald R Senger
Harold F Dvorak
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of PT100975A publication Critical patent/PT100975A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT100975A 1991-10-18 1992-10-16 Compostos que tem como alvo o factor de permeabilidade vascular, constituidos por uma primeira parte de ligacao a um anticorpo especifico para vpf e por uma toxina como parte efectora PT100975A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77938491A 1991-10-18 1991-10-18

Publications (1)

Publication Number Publication Date
PT100975A true PT100975A (pt) 1994-02-28

Family

ID=25116273

Family Applications (1)

Application Number Title Priority Date Filing Date
PT100975A PT100975A (pt) 1991-10-18 1992-10-16 Compostos que tem como alvo o factor de permeabilidade vascular, constituidos por uma primeira parte de ligacao a um anticorpo especifico para vpf e por uma toxina como parte efectora

Country Status (5)

Country Link
US (2) US5659013A (pt)
AU (1) AU2861692A (pt)
PT (1) PT100975A (pt)
WO (1) WO1993008210A1 (pt)
ZA (1) ZA928014B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US6762290B1 (en) * 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US6022541A (en) * 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
ATE239506T1 (de) * 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1995006131A1 (en) * 1993-08-23 1995-03-02 Monash University A method for the assay, prophylaxis and/or treatment of human disease conditions
HU220347B (hu) * 1994-07-11 2001-12-28 Board Of Regents The University Of Texas System Készítmény az érrendszer specifikus koagulálásához
US6426335B1 (en) * 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
AU7348998A (en) * 1997-05-16 1998-12-08 Hospital For Sick Children, The Inhibition of angiogenesis by verotoxins
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
EA200001007A1 (ru) 1998-03-31 2001-04-23 Дюпон Фармасьютикалз Компани Фармацевтические препараты для визуализации ангиогенных расстройств
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) * 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AU2371400A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
CN1356913A (zh) 1998-12-18 2002-07-03 杜邦药品公司 玻连蛋白受体拮抗剂药物
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6314314B1 (en) 1999-01-14 2001-11-06 Seth J. Karp Method for locating an internal bleeding site in a human body
GB9909392D0 (en) * 1999-04-24 1999-06-23 Imp Cancer Res Tech Treatment, imaging and diagnosis of disease
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6352500B1 (en) 1999-09-13 2002-03-05 Isotron, Inc. Neutron brachytherapy device and method
US6319189B1 (en) 1999-09-13 2001-11-20 Isotron, Inc. Methods for treating solid tumors using neutron therapy
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
ATE425255T1 (de) * 2000-03-31 2009-03-15 Imclone Systems Inc Antagonistische antikörper gegen ve-cadherin ohne negative effekte auf die vaskuläre permeabilität
US6817995B1 (en) 2000-04-20 2004-11-16 Isotron ,Inc. Reinforced catheter connector and system
US6497645B1 (en) 2000-08-28 2002-12-24 Isotron, Inc. Remote afterloader
US20030129193A1 (en) * 2001-09-27 2003-07-10 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coaguligand treatment
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US20060024229A1 (en) * 2004-07-29 2006-02-02 Seth Karp Method and product for locating an internal bleeding site
US20080167544A1 (en) * 2006-12-01 2008-07-10 Cold Spring Diagnostics, Inc. Compositions And Methods For Locating An Internal Bleeding Site
AU2009228158B2 (en) 2008-03-27 2014-02-27 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRbeta and VEGF-A
US8328728B2 (en) * 2008-08-22 2012-12-11 Pacesetter, Inc. Implantable hemodynamic monitor and methods for use therewith
KR101093717B1 (ko) * 2008-11-26 2011-12-19 한국생명공학연구원 Ｖｅｇｆ―특이적인 인간항체
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
LT3597037T (lt) 2012-06-12 2021-06-10 Regeneron Pharmaceuticals, Inc. Humanizuoti gyvūnai, išskyrus žmones, su apribotu imunoglobulino sunkiosios grandinės lokusu

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor

Also Published As

Publication number Publication date
AU2861692A (en) 1993-05-21
US5866127A (en) 1999-02-02
US5659013A (en) 1997-08-19
WO1993008210A1 (en) 1993-04-29
ZA928014B (en) 1993-04-26

Similar Documents

Publication Publication Date Title
PT100975A (pt) Compostos que tem como alvo o factor de permeabilidade vascular, constituidos por uma primeira parte de ligacao a um anticorpo especifico para vpf e por uma toxina como parte efectora
FI972580A (fi) Valmisteita ja menetelmiä ihoärsytyksen vähentämiseksi
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
PT98905A (pt) Processo para a preparacao de mono-hidrato de furoato de mometasona,e de composicoes farmaceuticas que o contem
MX9205443A (es) 4-alcoxi-pirimidinas sustituidas, procedimientos para su preparacion, agentes que las contienen, y su utilizacion como agentes plaguicidas.
MX9205280A (es) Derivados de benzanilida, procedimiento para su preparacion y composicion farmaceutica que los contiene.
FI950697A (fi) IL-4:n ja/tai IL-10:n uudet käytöt ja vasta-aineet niitä vastaan
SV2001000004A (es) Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa
FR2686857B1 (fr) Amortisseur de jambe de train d'atterrissage d'aeronef.
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
MX9102580A (es) Nuevas benzodiacepinonas, procedimiento para su preparacion y composicion farmaceutica que las contiene.
ES2102458T3 (es) Composiciones cationicas para la piel.
SV1998000139A (es) Procedimiento para la preparacion de acidos 8-metoxi-quinoloncarboxilicos ref.lea 32634-sv
BR9812718A (pt) Uso de pelo menos 0,5%, em peso, de água como um aditivo em uma composição de vaporizador para cabelo, e, composição de vaporizador para cabelo
MX24890A (es) Polipeptido sintetico, procedimiento par su preparacion y composicion farmaceutica que lo contiene.
NO900612L (no) Preservativ for vandige sammensetninger.
ES2174297T3 (es) Nuevos derivados de piranosidos.
BR0011261A (pt) Composição oral compreendendo perlita, e, uso de perlita
NO870941D0 (no) Vandige preparater med fytotoksisk virkning.
MX9100181A (es) Composicion viradora,electrostatica,que comprende resinas degradables
MX9100886A (es) Activador de plasminogeno hibrido,procedimiento para su preparacion y composiciones farmaceuticas que lo contienen
FI962979A0 (fi) Hirudiinia sisältävät farmaseuttiset koostumukset
MX24831A (es) Composicion para controlar infecciones fungicas de animales de acuacultivo.
MX9205996A (es) Nuevo compuesto antibiotico con actividad antitumoral, composicion farmaceutica que lo contiene y procedimiento para su preparacion.
BR9300855A (pt) Composicao,estrutura cimentosa,metodo para melhorar a estabilidade de uma estrutura cimentosa,e metodo para obter uma estrutura cimentosa

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19930630

FC3A Refusal

Effective date: 19990518